These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36991538)

  • 21. Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany.
    Böhmer MM; Walter D; Falkenhorst G; Müters S; Krause G; Wichmann O
    BMC Public Health; 2012 Oct; 12():938. PubMed ID: 23113995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Technical guidelines for seasonal influenza vaccination in China (2019-2020)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Jan; 54(1):21-36. PubMed ID: 31914565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
    Shinde V; Cho I; Plested JS; Agrawal S; Fiske J; Cai R; Zhou H; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou B; Lewis M; Price-Abbott P; Patel N; Massare MJ; Smith G; Keech C; Fries L; Glenn GM
    Lancet Infect Dis; 2022 Jan; 22(1):73-84. PubMed ID: 34563277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season.
    Serradell L; Wagué S; Moureau A; Nissilä M; Chabanon AL
    Hum Vaccin Immunother; 2021 Apr; 17(4):1205-1210. PubMed ID: 32966139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season.
    Machado MAA; Gandhi-Banga S; Gallo S; Cousseau TG; Byrareddy RM; Nissilä M; Schelling J; Monfredo C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2322196. PubMed ID: 38448394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved post-marketing safety surveillance of quadrivalent inactivated influenza vaccine in Mexico using a computerized, SMS-based follow-up system.
    Betancourt-Cravioto M; Cervantes-Powell P; Tapia-Conyer R; Ledlie S; Gandhi-Banga S
    Hum Vaccin Immunother; 2022 Dec; 18(1):1935170. PubMed ID: 34406896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.
    Bettinger JA; De Serres G; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; Top KA; Isenor JE; McCarthy AE;
    Euro Surveill; 2020 Jun; 25(22):. PubMed ID: 32524947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
    Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety profile of
    Puente Gómez I; Verheust C; Hanssens L; Dolhain J
    Expert Rev Vaccines; 2020 Aug; 19(8):771-779. PubMed ID: 32729745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Technical guidelines for seasonal influenza vaccination in China (2018-2019)].
    Feng LZ; Peng ZB; Wang DY; Yang P; Yang J; Zhang YY; Chen J; Jiang SQ; Xu LL; Kang M; Chen T; Zheng YM; Zheng JD; Qin Y; Zhao MJ; Tan YY; Li ZJ; Feng ZJ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Nov; 52(11):1101-1114. PubMed ID: 30419692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
    Fan R; Huang X; Nian X; Ou Z; Zhou J; Zhang J; Zeng P; Zhao W; Deng J; Chen W; Chen S; Duan K; Chen Y; Li X; Zhang J; Yang X
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-9. PubMed ID: 34473607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Moro PL; Woo EJ; Marquez P; Cano M
    Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.
    Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB
    MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.